2026 Pipeline Outlook: GLP‑1 expansion, first-in-class therapies, biosimilars, and gene therapies will drive significant changes in drug spend, access, and patient outcomes.
Specialty Trend & Employer Impact: The high volume of specialty drug approvals anticipated in 2026 will have major implications for employer budgets, benefit design, and member health outcomes.
Strategic Planning & Formulary Management: True Rx Health Strategists can help you proactively adjust formulary strategies to balance innovation, member access, and cost control in response to upcoming pipeline shifts.
Fill out our contact form and we will schedule an ideal time to hear what’s on your mind.